WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Organon & Co. (NYSE: OGN) between October 31, 2024 and April 30, 2025, both dates inclusive (the “Class ...

Organon's Q1 2025 earnings report showed significant declines across key financial metrics, leading to a drastic 30% drop in share price following a >90% dividend cut. The company's revenue ...

Organon, a women’s health-focused pharma company based in Jersey City, expects to eliminate 93 jobs as part of an effort to optimize internal operations. In a filing with the state Department of ...

Organon does not currently expect to record any milestone expense in the fourth quarter of 2024. Organon’s fourth quarter and full year 2024 results have not been finalized and are subject to ...

Her Health Finder empowers women to take charge of their health,” said Carole Lopez, Organon’s External Affairs and Communications Lead for Singapore, Hong Kong, Indonesia, and the Philippines.

To properly understand Organon's profit results, we need to consider the US$162m expense attributed to unusual items. While deductions due to unusual items are disappointing in the first instance ...

We have the right to choose what’s best for us and our family,” said Carole Lopez, Organon’s External Affairs and Communications Lead for Singapore, Hong Kong, Indonesia, and the Philippines.

Please provide your email address to receive an email when new articles are posted on . Organon is an independent global health care company dedicated to promoting women’s health. Organon will ...

Organon is broadening its presence in dermatology with a deal to acquire Dermavant, a company whose main asset is a commercialized plaque psoriasis drug that could soon expand its approval to ...

During the workshop, Carole Lopez, market access, policy, and communication lead of Organon SHIP Sub-Cluster (Singapore, Hong Kong, Indonesia, and the Philippines), said, “At Organon, we advocate for ...